Johnson & Johnson company, one of the largest healthcare product conglomerates, has acquired the Swiss firm Actelion Ltd., responsible for drug manufacturing, for USD 30 billion.

Acquisition for USD 30 billion

According to company plans, the new acquisition will be responsible for research and development. J&J aims to own 16% of the shares in Actelion, while the remaining shares will go to Swiss companies. Actelion has been known in the market for over 20 years. It was a family-owned firm founded by the president — Jean-Paul Clozel — and his wife — Martine Clozel. The team also includes a number of specialists who previously left the Roche holding.

Summary

Acquisition of Actelion for USD 30 billion

Johnson & Johnson is buying Actelion Ltd. for USD 30 billion. The Swiss firm, known for over 20 years, will be responsible for research and development, while J&J will hold 16% of its shares. The remaining shares will go to Swiss companies.

Actelion is a family-owned business founded by Jean-Paul and Martine Clozel. The team includes specialists who previously left the Roche holding.